Illumina

With the Illumina 5-base solution, researchers can capture genomic variants and methylation events simultaneously in a single run, enabling a streamlined workflow and richer context for biomarker research in cancer and genetic disease. See how the Illumina 5-base solution is advancing research: https://bit.ly/45x6BZB

We’ve expanded the reach and impact of precision oncology — bringing it closer to where care happens. Our FDA-approved TruSight Oncology Comprehensive assay delivers comprehensive genomic profiling that is easy to use in-house. It reduces barriers, accelerates decisions, and expands access to precision medicine directly at the point of patient care, whether in a community hospital, oncology practice, or academic medical center. Yesterday, we announced CMS reimbursement to make this tool more accessible. Read more about this important diagnostic innovation from our VP and Head of Clinical Solutions, Traci Pawlowski: https://lnkd.in/eNi4tGbR

A big moment for precision oncology — CMS has granted reimbursement for Illumina’s FDA-approved TruSight™ Oncology (TSO) Comprehensive test. Now, more labs can offer comprehensive genomic profiling, and more clinicians can deliver personalized results for their patients, supporting better care and outcomes. It’s all part of our mission to expand access to genomic insights and improve human health. Read more about this exciting milestone: https://bit.ly/4qXNX67

“2026 will be a revolutionary year for precision health.” ✍️ CEO Jacob Thaysen shares his outlook on the year ahead, and how Illumina is redefining what’s possible. 🔗 https://lnkd.in/gqBZywUS

CEO Jacob Thaysen sat down with Bloomberg at #JPM2026 to discuss Illumina's achievements in 2025 and share what’s energizing us for the year ahead: 📈 Continued growth 🏥 Accelerating the global shift from sick care to health care 🌏 Expanding opportunities globally 🔬 Rising momentum as academic researchers are poised for a strong return Focused strategy. Strong execution. Great results — and much more ahead. Watch the interview here 🔗 : https://lnkd.in/gCX7PMHn

STAT 📰: Illumina launches massive cell atlas to fast-track drug discovery👇 Today, Jonathan Wosen, PhD reported on the Illumina Billion Cell Atlas, which is “based on the results of turning on or off genes across 200 cell lines, including lines used to study heart disease, neurologic disorders, immune conditions, and cancer.” Dive into the story in STAT, and check out our new page exploring this groundbreaking tool: https://lnkd.in/guhpN4nz https://lnkd.in/g-Agn6mw

1 billion cells. One atlas. Today, Illumina introduces the Billion Cell Atlas, creating the most comprehensive map of human disease biology — and unlocking unparalleled speed and scale in AI for drug discovery.   With AstraZeneca, Merck, and Eli Lilly and Company as founding participants, the Atlas will help researchers study the effect of switching on and off all 20,000 genes in cells linked to diseases that have been historically difficult to decode, including cardiology, neurology, immunology, rare genetic diseases, and cancer.   CEO Jacob Thaysen calls the Atlas an "unparalleled resource for training the next generation of AI models for precision medicine and drug target identification.”   Learn how the Atlas will elucidate the biological pathways behind some of the world’s most devastating diseases: https://lnkd.in/gM7q7VmW #JPM2026

Illumina recently built its 1000th NovaSeq X System, a milestone reflecting rapid global adoption of the platform for genomic research. The system is designed to help researchers analyze larger cohorts, achieve deeper sequencing, and support more data-intensive applications that enable insights in cancer research, genetic disease, and multiomics. This achievement demonstrates the scale, reliability, and operational rigor scientists depend on as they run data-intensive studies with the NovaSeq X System. Explore how it's advancing what’s possible in sequencing: https://bit.ly/47It6vO

At #CES2026, CEO Jacob Thaysen discussed how AI and DNA sequencing data are transforming our understanding of biology, accelerating drug discoveries, and revolutionizing disease diagnosis at unprecedented speed. But the data challenges of genomics require extraordinary compute power. That’s what makes our partnership with AMD so essential to our mission. If you missed our main stage discussion with AMD CEO Lisa Su, watch it here: https://bit.ly/4jBLqw6

At Illumina, we know that together, we can create a sustainable future. Tackling global challenges like food insecurity and conservation requires collaboration across communities. That’s why we’ve created innovative genomic solutions that support researchers and farmers worldwide to develop more productive and sustainable practices. This weekend, we are at the Plant & Animal Genome Conference to share how our microarray and NGS solutions empower researchers to: ✅ Advance sustainable agriculture ✅ Reduce food insecurity ✅ Support species conservation and protect biodiversity Stop by booth 303 at #PAG33 to learn more. Together, we can build a healthier planet for generations to come. Learn more about how we are transforming the future of agriculture: https://bit.ly/4swyCej